Merck.......HIV Success.............

Last decade there was hue and cry for treatment of AIDS, Many of the large pharmaceutical companies went on to target CCR5 inhibitors but there was one young scientist in Merck who went against all odds and said that Merck scientist should focus on Integrase inhibitors, it was a risk at Merck's end as its competitors were working on other targets, Later on Merck's Integrase inhibitor drug Isentress, was approved in 2006 and it went on to become Merck's fastest growing medicine last quarter. Sales of the twice-a-day drug jumped 123% to $172 million in the second quarter at a time when the overall U.S. drug market may shrink for the first time in decades. On July 9, this year the drug was approved as a choice for patients who are just beginning treatment. It is been estimated that the Drug will generate around $2 billion of revenue by this year end .........